Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size are small enough to be filtered through a 220 nm membrane, and in general are below 120 nm. Such vaccine compositions have superior immunological properties.
展开▼